US Bipartisan Bill Seeks to Regulate Investments in Chinese High-Tech Firms
US senators are preparing a bipartisan bill that would require US investors targeting Chinese high-tech...
Fineline Cube
Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052
China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...
Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...
Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...
WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake
China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...
Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...
Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...
China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies
China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement...
Clover Biopharmaceuticals Initiates SCB-219M Clinical Study for CIT Treatment
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the first subject dosing in a Phase...
Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...
Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases
Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ:...
Soaring Costs of Cynomolgus Monkeys Impact China’s Biologic Drug Development
Cynomolgus monkeys, or macaques, used in laboratory experiments have seen their value skyrocket due to...
Shanghai Henlius Partners with Organon for Global Biosimilar Commercialization
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) has entered into a licensing and supply agreement...
BeiGene’s Brukinsa Faces Three-Month FDA Approval Delay for CLL/SLL Indication
China-based biotech company BeiGene Inc. (Nasdaq: BGNE) will experience a three-month delay in its pursuit...
Junshi Biosciences Receives NMPA Approval for Fourth-Generation EGFR Inhibitor WJ13404
Shanghai-based biotech Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from China’s National Medical...
Innovent Biologics Receives BPOM Approval for Bevagen in Indonesia
China-based Innovent Biologics Inc. (HKG: 1801) has announced receiving indication approvals from Indonesia’s Badan Pengawas...
Innovent Biologics’ IBI306 Accepted for Review by China’s NMPA for Hypercholesterolemia
China-based Innovent Biologics Inc. (HKG: 1801) has announced that a New Drug Application (NDA) filing...
NHSA Releases Draft Proposals for NRDL Annual Renewal Process
The National Healthcare Security Administration (NHSA) has formulated and released draft proposals for rules covering...
Clover Biopharmaceuticals Begins Phase III Trial for COVID-19 Booster SCB-2019
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the immunization of the first group of...
InventisBio’s KRAS G12C Inhibitor D-1553 Earns CDE Breakthrough Therapy Status
China-based InventisBio (Shanghai) Co., Ltd announced receiving breakthrough therapy designation (BTD) status for its KRAS...